Jun Shiihara
Saitama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
First Reported Case of Pure Red Cell Aplasia Related to Sotorasib.
Journal: Internal medicine (Tokyo, Japan)
Published: September 04, 2024
A Case of Lung Cancer Exhibiting Pleoymorphic Carcinoma Transformation Resistance Following Treatment With Osimertinib That Was Successfully Treated Using Local Ablative Treatment.
Journal: Thoracic cancer
Published: August 29, 2024
Metastatic Pleomorphic Carcinoma of the Lung with Extensive Chromosomal Rearrangements: An Autopsy Case with a Literature Review.
Journal: Internal medicine (Tokyo, Japan)
Published: July 03, 2024
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Journal: JAMA oncology
Published: March 07, 2024
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 24, 2023
Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report.
Journal: Thoracic cancer
Published: July 24, 2023
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Journal: Cancer chemotherapy and pharmacology
Published: March 08, 2023
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Journal: Frontiers in oncology
Published: October 26, 2022
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer.
Journal: Oncology letters
Published: September 19, 2022
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Journal: Thoracic cancer
Published: July 05, 2022
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Journal: Investigational new drugs
Published: May 14, 2022
Immunoglobulin G4-related Pleuritis Complicated with Minimal Change Disease.
Journal: Internal medicine (Tokyo, Japan)
Published: September 06, 2021
Last Updated: 09/26/2026